SCHEMBL4415563

SCHEMBL4415563

CC1CCCCCCCCCCC(=O)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
TRIM24 O15164 2/20 0.52
TRIM33 Q9UPN9 2/20 0.52
ALDH1A1 P00352 2/20 0.52
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA4 P22748 1/20 0.50
ESR2 Q92731 2/20 0.33
EPHX1 P07099 1/20 0.33
LMNA P02545 1/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
CRBN Q96SW2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2197936 1.00 KMT2A (0.54) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL2691441 1.00 KMT2A (0.54) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL7934086 1.00 KMT2A (0.54) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL2689809 0.98 CA1 (0.52) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL6243332 0.95 KMT2A (0.58) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL6243018 0.95 KMT2A (0.58) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL4418871 0.93 KMT2A (0.56) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL2690225 0.90 CA1 (0.54) KMT2ATRIM24TRIM33ALDH1A1CA1
SCHEMBL441622 0.90
SCHEMBL2689503 0.85 TRIM24 (0.50) KMT2ATRIM24TRIM33ALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1236707-A1 Process for the preparation of macrocyclic ketones Givaudan SA (CH) 2002-09-04 EP claimed
EP-1362023-B1 METHOD FOR PRODUCING MACROCYCLIC KETONES GIVAUDAN SA (CH) 2009-04-15 EP disclosed
US-6951964-B2 Method for producing macrocyclic ketones GIVAUDAN SA (CH) 2005-10-04 US disclosed
US-20040082816-A1 Method for producting macrocyclic ketones GIVAUDAN SA (CH) 2004-04-29 US disclosed
EP-1362023-A1 METHOD FOR PRODUCING MACROCYCLIC KETONES Givaudan SA (CH) 2003-11-19 EP disclosed
WO-2002068372-A1 METHOD FOR PRODUCING MACROCYCLIC KETONES GIVAUDAN SA (CH) 2002-09-06 WO disclosed
EP-1236707-A1 Process for the preparation of macrocyclic ketones Givaudan SA (CH) 2002-09-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082816-A1 Method for producting macrocyclic ketones ADH1C, ADH1A, AKR1C3 KMT2A 3232/4885TRIM24 3080/4885TRIM33 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.